ClinicaliQ Trial Snapshot
- AIC Genotyping Study — Recruiting • Cardiology / Cardiovascular • NCT07574697.
- What is being tested: Genetic variants within a targeted dilated cardiomyopathy (DCM) gene panel are being analysed to identify and characterise genetic differences between patients with atrial fibrillation-induced cardiomyopathy (AIC) and control groups (both positive and negative controls).
- Patient eligibility overview: The study recruits patients with AF-induced cardiomyopathy as the primary group, alongside positive control participants (likely those with known genetic DCM) and negative controls (unaffected individuals), enabling comparative genetic analysis across these distinct populations.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
To quantify genetic variants in a focused DCM gene panel among AF-induced cardiomyopathy (AIC) and positive/negative controls
Eligibility Snapshot
- INCLUSION: AIC (Cases): * Age ≥18 * Persistent AF before index catheter ablation or cardioversion * LVEF ≤40% during rate-controlled (resting HR 21 units/week. * Any history of cardiotoxic chemotherapy. AF/HF non-responders (Positive controls) * No alternative cause for LVSD (ischemic cardiomyopathy/non-ischaemic cardiomyopathy before AF diagnosis, primary valve disease, inherited cardiomyopathy). * Any pregnancy during AF or in the 12 months preceding LVSD onset. * Alcohol intake >21 units/week. * Any history of cardiotoxic chemotherapy.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.